CAS
CSTL icon

Coppell Advisory Solutions’s Castle Biosciences CSTL Stock Holding History

Coppell Advisory Solutions’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,924
Closed -$51.3K – 639
2024
Q4 		$51.3K Buy
1,924
+1
+0.1% +$30 0.01% 576
2024
Q3 		$53.6K Sell
1,923
-120
-6% -$3.05K 0.01% 534
2024
Q2 		$44.5K Buy
+2,043
New +$45.5K 0.01% 528
2023
Q4 		$25.7K Buy
+1,190
New +$20.9K 0.01% 662

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Coppell Advisory Solutions's CSTL Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 1,924 shares — an estimated $51.3K sold.

Coppell Advisory Solutions first reported a position in CSTL in Q4 2023 and held it in 4 quarters. The position peaked at $53.6K in Q3 2024. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 1,924 Castle Biosciences shares in Q1 2025, an estimated $51.3K.
  • Coppell Advisory Solutions first reported a position in Castle Biosciences in Q4 2023 and held it in 4 quarters.
  • Coppell Advisory Solutions's Castle Biosciences position peaked at $53.6K in Q3 2024.
  • 180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.